0
Poster Presentations: Wednesday, October 26, 2011 |

Extracellular Beta Nicotinamide Adenine Dinucleotide (B-NAD) - Is This the Molecule to Treat Acute Lung Injury and Adult Respiratory Distress Syndrome? FREE TO VIEW

Pritam Neupane, MBBS; Supriya Sridhar, PhD; Rudolf Lucas, PhD; Alexander Verin, PhD; Nagavedi Umapathy, PhD
Chest. 2011;140(4_MeetingAbstracts):586A. doi:10.1378/chest.1118208
Text Size: A A A
Published online

Abstract

PURPOSE: Endothelial hyperpermeability represent a major hallmark of acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). B-nicotinamide adenine dinucleotide (B-NAD) is one of the naturally occurring substances found in all living cells which when released into the extracellular fluids under pro-inflammatory conditions from several cell sources including endothelium elicit enhancement of barrier function of human pulmonary artery endothelial cells (HPAEC) via P2Y1/Y11 receptors. To study the protective effects of B-NAD (post-treatment) against various agents of endothelial cell (EC) barrier dysfunction namely Thr (thrombin, protease), LPS (lipopolysaccharide), and PLY (pneumolysin), in vitro. To elicit the signaling pathways responsible for B-NAD induced enhancement of EC barrier function.

METHODS: Enhancement of HAPEC barrier function by B-NAD and its protective effect against disruptive molecules LPS, PLY and Thr was characterized by measurement of transendothelial electrical resistance (TER) after the addition of these molecules, using electrical cell-substrate impedance sensing (ECIS). Controlled study of Gq siRNA transfected HPAEC was performed to identify the involvement of Gq signaling pathway in B-NAD induced enhancement of EC barrier function.

RESULTS: Our results suggest that post treatment of B-NAD is protective and attenuate the HPAEC barrier dysfunction induced by LPS, PLY and Thr. Our data also suggest that siRNA based silencing of Gq protein attenuate the B-NAD-induced EC barrier enhancement and therefore, Gq pathway is also involved in B-NAD mediated signaling.

CONCLUSIONS: B-NAD is thus a very efficient regulator of HPAEC integrity and is protective against various barrier disruptive molecules. It acts through both Gs and Gq protein mediated pathways.

CLINICAL IMPLICATIONS: Unpublished mice studies have demonstrated survival benefit in B-NAD treated subjects in LPS-induced sepsis model. Thus better understanding of mechanisms of EC barrier function can contribute to the development of alternative therapeutic strategies for ALI/ARDS and B-NAD may represent a therapeutic potential in clinical settings.

DISCLOSURE: The following authors have nothing to disclose: Pritam Neupane, Supriya Sridhar, Rudolf Lucas, Alexander Verin, Nagavedi Umapathy

No Product/Research Disclosure Information

09:00 AM - 10:00 AM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543